Exploring Therapeutic Avenues in HER2+ Breast Cancer

Opinion
Video

Experts delve into post–KATHERINE trial discussions, examining data and its impact on residual disease. They highlight unmet needs, emphasizing the ongoing CompassHER2 RD trial’s potential to address challenges, especially regarding brain metastases.

This is a video synopsis/summary of a Peer Exchange involving Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO.

O’Shaughnessy and Rugo discuss the potential of neratinib in addressing residual disease after T-DM1 treatment in patients with HER2-positive breast cancer. The external study showed positive results, especially in patients who are estrogen-receptor positive, highlighting the need for additional therapies to prevent metastasis. O’Shaughnessy acknowledges the ongoing CompassHER2 RD trial’s aim to reduce the risk of brain metastasis by combining T-DM1 (trastuzumab emtansine) with tucatinib. Isaacs stresses the importance of enrolling patients in trials targeting brain metastases, aiming for better standards of care. The discussion emphasizes the optimization of endocrine therapy for HER2-positive patients and ongoing efforts to improve treatment strategies in both adjuvant and metastatic settings.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.

Related Videos
Video 18 - "Reflecting on Differentiated Thyroid Cancer: Final Insights"
Video 17 - "Phase 2 ATLEP Trial Results"
Video 10 -"Real-World Evidence on Second-Line Therapy Selection and Outcomes"
Video 9 - "Additional Second-Line Treatments for HCC"
Video 16 - "Neoadjuvant Approach in RAI-R-DTC"
Video 15 - "Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment"
Video 8 - "The Evolving Landscape of Second-Line Therapies in HCC Management"
Video 7 - "Comorbidity Considerations for HCC Treatment"
Video 8 - "Future Outlook for RET Fusion-Targeted Therapies"
Video 7 - "Impact and Positioning of Tumor Agnostic Approvals"
Related Content